- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Including Panobinostat Improves PFS in Multiple Myeloma
Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.
The addition of panobinostat to bortezomib and dexamethasone significantly extended PFS among patients with relapsed or relapsed/refractory multiple myeloma, according to results of the randomized phase 3 PANORAMA1 trial.
Preclinical studies showed panobinostat (LBH589, Novartis) — an oral pan-deacetylase inhibitor — has anti-myeloma activity when combined with bortezomib (Velcade, Millennium) and dexamethasone.
In the current study, Jesús F. San-Miguel, MD, PhD, head of the department of hematology at the University Hospital of Salamanca in Spain, and colleagues sought to compare bortezomib, dexamethasone and panobinostat with bortezomib, dexamethasone and placebo.
The analysis included 768 patients (median age, 63 years) with relapsed or relapsed/refractory multiple myeloma. About half of patients (48%) had received two or three prior regimens, and 57% had undergone prior autologous stem cell transplant.
Read the complete report on Healio: http://bit.ly/1wjWYoY
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
